GGZ-gids: doelmatigheid en kwaliteit van voorschrijven van antidepressiva


  1. Zorgverzekeraars Nederland en GGZ Nederland (2007), pp.132-150.
  2. Multidisciplinaire richtlijn Depressie.
  3. Richtlijn Depressie [ingezonden]. MGV 2006; 61: 2-5.
  4. www.stichtingpandora.nl
  5. Watanabe N, et al. Mirtazapine versus other anti-depressive agents for depression (Protocol). Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No.:CD006528. DOI: 10.1002/14651858. CD006528.
  6. Cipriani A, et al. Venlafaxine versus other anti-depressive agents for depression (Protocol). Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No.:CD006530. DOI: 10.1002/14651858. CD006530.
  7. Updated prescribing advice for venlafaxine (Efexor/Efexor XL). (31 mei 2006). Te downloaden via www.mhra.gov.uk/NewsCentre/Pressreleases/CON2023843.
  8. Cipriani A, et al. Venlafaxine for major depression [Editorial]. BMJ 2007; 334: 215-216.
  9. Rubino A, et al. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ 2007; 334: 242.
  10. Whyte IM, et al. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 2003; 96: 369-374. 
  11. www.mhra.gov.uk/Newscentre/CON2015023 (5 april 2005)
  12. Eaton L (2005) Drug company is reprimanded by UK regulator. BMJ 330, 865 (16 april).
  13. Thase ME, et al. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 2001; 178: 234-241.
  14. www.fda.gov/cder/warn/2004/Effexor.pdf.  
            

Auteurs

  • dr D. Bijl, dr W. van den Burg